Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Jun 29;9:3939–3949. doi: 10.2147/OTT.S105245

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2016 Xing et al. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

Recombinant CXCL16 (IC₅₀ value) displays inhibitory effects on Tregs and GIST cells in vitro.

Notes: (A) The proliferation ratio was determined by MTT assays. (B) Cells were stained with propidium iodide and fluorescence-activated cell sorting analysis was performed. (C) Transwell assays were performed to detect migration and invasion of cells. Cells that migrated to the bottom of the membrane were stained and counted. Treg: untreated Tregs; Treg-C: Tregs treated with recombinant CXCL16; Treg-C+S: Tregs treated with recombinant CXCL16 and CXCR6 siRNA; GIST-T1: untreated GIST-T1 cells; GIST-T1-C: GIST-T1 cells treated with recombinant CXCL16; GIST-T1-C+S: GIST-T1 cells treated with recombinant CXCL16 and CXCR6 siRNA; GIST882: untreated GIST882 cells; GIST882-C: GIST882 cells treated with recombinant CXCL16; GIST882-C+S: GIST882 cells treated with recombinant CXCL16 and CXCR6 siRNA.

Abbreviations: GIST, gastrointestinal stromal tumors; PI, propidium iodide; IC₅₀, half maximal inhibitory concentration; rhCXCL16, recombinant human CXCL16.

Recombinant CXCL16 (IC₅₀ value) displays inhibitory effects on Tregs and GIST cells in vitro.

Notes: (A) The proliferation ratio was determined by MTT assays. (B) Cells were stained with propidium iodide and fluorescence-activated cell sorting analysis was performed. (C) Transwell assays were performed to detect migration and invasion of cells. Cells that migrated to the bottom of the membrane were stained and counted. Treg: untreated Tregs; Treg-C: Tregs treated with recombinant CXCL16; Treg-C+S: Tregs treated with recombinant CXCL16 and CXCR6 siRNA; GIST-T1: untreated GIST-T1 cells; GIST-T1-C: GIST-T1 cells treated with recombinant CXCL16; GIST-T1-C+S: GIST-T1 cells treated with recombinant CXCL16 and CXCR6 siRNA; GIST882: untreated GIST882 cells; GIST882-C: GIST882 cells treated with recombinant CXCL16; GIST882-C+S: GIST882 cells treated with recombinant CXCL16 and CXCR6 siRNA.

Abbreviations: GIST, gastrointestinal stromal tumors; PI, propidium iodide; IC₅₀, half maximal inhibitory concentration; rhCXCL16, recombinant human CXCL16.